RxDoctor Payments Data

Troy Tada, DO

Pain Medicine · Honolulu, HINPI 1407114713

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.9% of the total across 606 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $5,174 and has fallen 60.0% since, to $2,068 in 2025.

$17,853in general payments, 2019–2025

Across 606 payments — averaging $29.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Medtronic$3K
  • Boston Scientific$2K
  • Vertiflex, Inc.$1K
  • AbbVie$1K
  • Nevro Corp.$1K
  • plus $6K from 36 others

What the payments were for

  • Travel & lodging$1,0926%
  • Food & beverage$16,75794%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pain medicine providers in Hawaiito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$177,487
Medicare patients
136
Services billed
5,076

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl57$38,903
Diclofenac Epolamine81$36,697
OxycontinOxycodone Hcl65$30,240
MovantikNaloxegol Oxalate62$25,281
Buprenorphine85$19,288
SymproicNaldemedine Tosylate26$13,753
TrintellixVortioxetine Hydrobromide17$9,246
Oxycodone Hcl399$6,126
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen170$5,121
Gabapentin141$3,848
Pregabalin153$3,523
Morphine Sulfate ErMorphine Sulfate102$3,487
Lidocaine44$3,463
Lubiprostone14$3,451
Duloxetine Hcl81$3,436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$256$9,24617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pain medicine providers in Hawaiion file to place this against a meaningful peer group, so we don't.

Other pain medicine in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →